Euphrasia Eye Drops in Preterm Infants With First Signs of Congestion of Nasolacrimal Duct
Status:
Completed
Trial end date:
2016-12-16
Target enrollment:
Participant gender:
Summary
Congenital nasolacrimal duct obstruction (CNLDO) occurs in approximately 10 to 20% of all
term newborns, and is the most common cause of persistent tearing and ocular discharge in
children. CNLDO causes symptoms in up to 6% of children during the first year of life. The
first clinical signs appear during the first month of life in 95% of cases and usually
consist of tearing and debris on the eyelashes ("mattering"). Mucopurulent eye discharge
occurs commonly in infants with CNLDO and, in the absence of other signs of infection,
suggests bacterial overgrowth in the stagnant tear pool of the lacrimal sac.
This study investigates whether early administration of Euphrasia eye drops (Weleda AG,
Arlesheim) in preterm neonates presenting with first ocular discharge with or without tearing
and reddened eye fosters the resolution of the ocular discharge and reduces the need for
topical antibiotic therapy.